NDAORALTABLET
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
DUZALLO (allopurinol; lesinurad) by Ironwood Pharmaceuticals is allopurinol acts on purine catabolism, without disrupting the biosynthesis of purines. Approved for leukemia, lymphoma. First approved in 2017.
Drug data last refreshed 13m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DUZALLO is a fixed-dose oral combination of allopurinol (a xanthine oxidase inhibitor) and lesinurad (a uricosuric agent) approved in 2017 for hyperuricemia in patients with gout, leukemia, and lymphoma. It reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine to uric acid, while lesinurad enhances renal uric acid clearance. The dual mechanism addresses both production and excretion pathways of uric acid.
Peak5.7 years to LOE
DUZALLO is at peak lifecycle as of the 2017 approval, suggesting established market presence and moderate commercial team support at Ironwood Pharmaceuticals.
Mechanism of Action
Allopurinol acts on purine catabolism, without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. Allopurinol is a structural analogue of the natural purine base, hypoxanthine. It is an…
Worked on DUZALLO at Ironwood Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.